BR112022014949A2 - Compostos e usos dos mesmos - Google Patents
Compostos e usos dos mesmosInfo
- Publication number
- BR112022014949A2 BR112022014949A2 BR112022014949A BR112022014949A BR112022014949A2 BR 112022014949 A2 BR112022014949 A2 BR 112022014949A2 BR 112022014949 A BR112022014949 A BR 112022014949A BR 112022014949 A BR112022014949 A BR 112022014949A BR 112022014949 A2 BR112022014949 A2 BR 112022014949A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- present
- disorders related
- methods useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSTOS E USOS DOS MESMOS. A presente invenção apresenta compostos e métodos úteis para o tratamento de transtornos relacionados ao complexo BAF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967565P | 2020-01-29 | 2020-01-29 | |
| PCT/US2021/015944 WO2021155321A2 (en) | 2020-01-29 | 2021-01-29 | Compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014949A2 true BR112022014949A2 (pt) | 2022-09-27 |
Family
ID=77079308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014949A BR112022014949A2 (pt) | 2020-01-29 | 2021-01-29 | Compostos e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230348452A1 (pt) |
| EP (1) | EP4097096A4 (pt) |
| JP (1) | JP2023512523A (pt) |
| KR (1) | KR20220146477A (pt) |
| CN (1) | CN115335373A (pt) |
| AU (1) | AU2021213258B2 (pt) |
| BR (1) | BR112022014949A2 (pt) |
| CA (1) | CA3166404A1 (pt) |
| IL (1) | IL295176A (pt) |
| MX (1) | MX2022009366A (pt) |
| WO (1) | WO2021155321A2 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022523074A (ja) * | 2019-01-29 | 2022-04-21 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| CN114773316B (zh) * | 2022-06-17 | 2022-10-25 | 上海睿跃生物科技有限公司 | 2-(2,6-二氧代-哌啶-3-基)-5-氟-异吲哚-1,3-二酮的制备方法 |
| WO2024064316A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
| WO2024064328A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2548618A3 (en) * | 2008-07-15 | 2013-02-27 | Novartis AG | Heteroaryl derivatives as DGAT1 inhibitors |
| CN112153984A (zh) * | 2018-01-30 | 2020-12-29 | 福宏治疗公司 | 化合物及其用途 |
| WO2019195201A1 (en) * | 2018-04-01 | 2019-10-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
-
2021
- 2021-01-29 EP EP21747487.3A patent/EP4097096A4/en active Pending
- 2021-01-29 CA CA3166404A patent/CA3166404A1/en active Pending
- 2021-01-29 BR BR112022014949A patent/BR112022014949A2/pt unknown
- 2021-01-29 CN CN202180025865.1A patent/CN115335373A/zh active Pending
- 2021-01-29 MX MX2022009366A patent/MX2022009366A/es unknown
- 2021-01-29 IL IL295176A patent/IL295176A/en unknown
- 2021-01-29 JP JP2022546433A patent/JP2023512523A/ja active Pending
- 2021-01-29 AU AU2021213258A patent/AU2021213258B2/en active Active
- 2021-01-29 WO PCT/US2021/015944 patent/WO2021155321A2/en active Application Filing
- 2021-01-29 US US17/795,615 patent/US20230348452A1/en active Pending
- 2021-01-29 KR KR1020227029588A patent/KR20220146477A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021213258B2 (en) | 2024-05-02 |
| CA3166404A1 (en) | 2021-08-05 |
| AU2021213258A1 (en) | 2022-08-25 |
| US20230348452A1 (en) | 2023-11-02 |
| JP2023512523A (ja) | 2023-03-27 |
| WO2021155321A2 (en) | 2021-08-05 |
| EP4097096A2 (en) | 2022-12-07 |
| KR20220146477A (ko) | 2022-11-01 |
| IL295176A (en) | 2022-09-01 |
| WO2021155321A3 (en) | 2021-09-23 |
| CN115335373A (zh) | 2022-11-11 |
| MX2022009366A (es) | 2022-10-27 |
| EP4097096A4 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014949A2 (pt) | Compostos e usos dos mesmos | |
| BR112022015110A2 (pt) | Compostos e usos dos mesmos | |
| BR112021016620A2 (pt) | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais | |
| BR112021016650A2 (pt) | Indóis substituídos por n e outros heterociclos para o tratamento de distúrbios cerebrais | |
| CU20210029A7 (es) | Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades | |
| BR112016029334A2 (pt) | produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos | |
| BR112022019991A2 (pt) | Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos | |
| EA201792231A1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| BR112015005117A2 (pt) | métodos de tratamento da doença de alzheimer e suas composições farmacêuticas | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
| BR112023021068A2 (pt) | Compostos, composições e métodos para tratar câncer | |
| BR112018069533A2 (pt) | tratamento de condições alérgicas oculares com ciclodextrinas | |
| ECSP12012309A (es) | Anticuerpos hacia gdf8 humano | |
| BR112018013522A2 (pt) | compostos inibidores de metaloenzima | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| UY37391A (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| BR112022011098A2 (pt) | Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados | |
| BR112022015109A2 (pt) | Compostos e usos dos mesmos | |
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| BR112018070357A2 (pt) | anticorpos anticomplemento contra o fator bb e seus usos | |
| BR112023020781A2 (pt) | Moduladores de cbl-b e usos dos mesmos | |
| DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
| BR112023014973A2 (pt) | Derivados de urolitina e métodos de uso dos mesmos | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos |